Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...
The in vivo cell therapy seed Carisma Therapeutics planted with Moderna in 2022 is starting to sprout. | The in vivo cell ...
During quarterly earnings calls across the medtech industry, a recurring question has been on investors’ minds: If ...
Johnson & Johnson MedTech will enter the U.S. pulsed field ablation market following an FDA green light for its Varipulse ...
Allogene Therapeutics has reported phase 1 data on its solid tumor CAR-T, linking the off-the-shelf cell therapy candidate to ...
NextCure is going all in on its preclinical B7-H4-directed antibody-drug conjugate (ADC). | NextCure is going all in on its ...
Each year, we dive into the world of biotech closures and layoffs, tracking the industry’s pulse as companies navigate | This ...
The FDA has placed a trial of Rapport Therapeutics’ epilepsy drug for a type of nerve pain on hold while the biotech tweaks ...
The FDA has cleared its first light-based therapy for dry age-related macular degeneration—which the agency described as ...
Dynavax is giving up work on its combination vaccine for tetanus, diphtheria and acellular pertussis (Tdap) after mulling phase 1 data for the shot. | Dynavax is giving up on its combination vaccine ...
ADC Therapeutics has stopped development of lead solid tumor candidate ADCT-601. The biotech axed the AXL-directed ...
MacroGenics has pumped the brakes on vobramitamab duocarmazine (vobra duo), pausing investment in additional opportunities ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback